Insider confidence sends shares soaring. United Therapeutics Corporation surged 14.8% to $600.09 on Monday, March 30, 2026, after a wave of insider buying totaling $12.4 million signaled strong conviction from the company’s top executives and board members.
Heavy buying across leadership. The specialty pharmaceutical maker saw significant insider purchases over the past 30 days, with CEO Martine A. Rothblatt leading the charge at $26.4 million across 180,500 shares. Board member James Edgemond acquired 20,000 shares worth $2.7 million, while Paul A. Mahon purchased 16,600 shares valued at $2.4 million. The most recent round of purchases occurred on March 26, when Edgemond bought 10,000 shares at $135.42 per share ($1.4 million), Rothblatt acquired 9,500 shares at $146.03 ($1.4 million), and board member Tommy G. Thompson added 2,000 shares at $101.80 ($0.2 million). Rothblatt had also purchased 9,500 shares on both March 25 and March 24, each at $146.03 per share.
Volume and market reaction. Trading volume reached 583,710 shares as investors interpreted the coordinated insider buying as a bullish signal about the company’s prospects. The move pushed United Therapeutics’ market capitalization to $26.3 billion. The stock also benefited from recent analyst support, with one firm raising its price target in the last seven days and no cuts recorded during that period.
Message from the top. Insider buying of this magnitude—particularly when led by the CEO—typically suggests management believes the stock is undervalued relative to upcoming developments or the company’s intrinsic worth. The purchases come at varying price points, with Rothblatt’s most recent buys at $146.03 representing a fraction of today’s $600.09 closing price, underscoring the conviction behind these transactions.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
